{"id":368295,"date":"2023-12-01T20:18:35","date_gmt":"2023-12-02T01:18:35","guid":{"rendered":"https:\/\/platohealth.ai\/what-a-pair-of-phase-ii-obesity-results-could-mean-for-altimmune-pfizer\/"},"modified":"2023-12-02T22:30:31","modified_gmt":"2023-12-03T03:30:31","slug":"what-a-pair-of-phase-ii-obesity-results-could-mean-for-altimmune-pfizer","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/what-a-pair-of-phase-ii-obesity-results-could-mean-for-altimmune-pfizer\/","title":{"rendered":"What a pair of Phase II obesity results could mean for Altimmune, Pfizer\u00a0","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

ARTICLE | Product Development<\/p>\n

\n
\n
\n

Will\u00a0Altimmune\u2019s pemvidutide be good enough to attract a partner? And will\u00a0Pfizer go shopping after latest danuglipron data?<\/h2>\n

\n By\u00a0<\/span>Selina Koch, Executive Editor, and Gunjan Ohri, Data Content Analyst<\/span>\n<\/p>\n

December 2, 2023 1:18 AM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/span><\/span><\/div>\n

Neither of Friday\u2019s Phase II obesity readouts, one from Altimmune and one from Pfizer, pointed to best-in-class potential. However, with efficacy similar to Wegovy, Altimmune could be positioned to partner. Pfizer, by contrast, has paused its twice-daily danuglipron program, which could send the pharma shopping for a new therapy.\u00a0<\/p>\n

After opening Friday up 82%, shares of Altimmune Inc.<\/a> (NASDAQ:ALT) finished the day up 13%, giving the company a market cap of about $192 million, as investors digested results from the Phase II MOMENTUM trial of pemvidutide. <\/span>…<\/p>\n